Human cytochrome P450s: selectivity and measurement in vivo

Reference

• ABEL, S. M., MAGGS, J. L., BACK, D. J. and PARK, B. K., 1991, Cortisol metabolism by human liver in vitro—I. Metabolite Identification and inter-individual v ariability journal of Steroid Biochemistry and Molecular Biology, 43, 713–719.
   Web of Science ®Google Scholar
• AHONEN, J., OLKKOLA, K. T. and NEUVONEN, P. J., 1995, Effects of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology, 40, 270–272.
   PubMed Web of Science ®Google Scholar
• AL-HADIDI, H. F., IRSHAID, Y. M. and RAWASHDEH, N. M., 1994, Metoprolol a-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians. European Journal of Clinical Pharmacology, 47, 311–314.
   Google Scholar
• ALVAN, G., BECHTEL, B., 'sums, L. and GUNDERT -REMY, U., 1990, Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. European Journal of Clinical Phar-macology, 39, 533–537.
   Google Scholar
• ANDERSSON T., 1991, Omeprazole drug interaction studies. Clinical Pharmacokinetics, 21, 195-212. ANDERSSON, T., MINERS, J. 0., VERONSE, M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both (S)-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131–137.
   Web of Science ®Google Scholar
• ANDERSSON, T., REGARDH, C. G., Lou, Y. C., ZHANG, Y., DAHL, ML. and BERTILSSON, L., 1992, Polymorphic hydroxylation of (S)-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics, 2, 25–31.
   PubMedGoogle Scholar
• ANGELO, M., DRING, L. G., LANCASTER, R., LATHAM, A. and SMITH, R. L., 1975, A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine. British Journal of Pharmacology, 55, 264P.
   PubMed Web of Science ®Google Scholar
• AOYAMA, T., YAMANO, S., WAXMAN, D. J., LAPENSON, D. P., MEYER, U. A., FISCHER, V., TYNDALE, R., INABA, T., KALOW, W., GELBOIN, H. V. and GONZALEZ, F. J., 1989, Cytochrome P-450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporin. Journal of Biological Chemistry, 264, 10388–10395.
   PubMed Web of Science ®Google Scholar
• BACK, D. J. and TEA, J. F., 1991, Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporing by human liver microsomes. British Journal of Clinical Pharmacology, 32, 5,624–6.
   PubMed Web of Science ®Google Scholar
• BERTILSSON, L., 1995, Geographical/interracial differences in polymorphic drug oxidation. Clinical Pharmacokinetic Concepts, 29, 192–209.
   PubMed Web of Science ®Google Scholar
• BERTILSSON, L., CARRILLO, J. A., DAHL, M. L., LLERENA, A., ALM, C., BONDESSON, U., LINDSTROM, L.,
   Google Scholar
• RODRIGUEZ -DE-LA-RUBIA, I., RAMOS, S. and BENITEZ, J., 1994, Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology, 38, 471–473.
   PubMed Web of Science ®Google Scholar
• BERTILSSON, L., HENTHRON, T. K., SANZ, E., TYBRING, G., SAWE, J. and VILLEN, T., 1989, Importance of genetic factors in the regulation of diazepam metabolism: relationship to (S)-mephenyto in, but not debrisoquine, hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 45, 348–355.
   PubMed Web of Science ®Google Scholar
• BLYCHERT, E., EDGAR, B., ELMFELDT, D. and HEDNER, T., 1991, A population study of the pharmacokinetics of felodipine. British Journal of Clinical Pharmacology, 31, 15–24.
   PubMed Web of Science ®Google Scholar
• BOOBIS, A. R., LYNCH, AM., MURRAY, S., DE LA TORRE, R., SOLANS, A., FARRE, M., SEGURA, J., GOODERHAM, N. J. and DAVIES, D. S., 1994, CYP1A2 catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Research, 54, 89–94.
   PubMed Web of Science ®Google Scholar
• BOZKURT, A., BASCI, N. E., IsEsnEK, A., SAYAL, A. and KAYAALP, SO., 1994, Polymorphic debrisoquin metabolism in a Turkish population. Clinical Pharmacology and Therapeutics, 55, 399–401.
   PubMed Web of Science ®Google Scholar
• BREYER-PFAFF, U., PFANDL, B., NILL, K., NUSSER, E., MONNEY, C., JONZ1ER -PEREY, M., BAETTIG, D. and BAUMANN, P., 1992, Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clinical Pharmacology and Therapeutics, 52, 350–358.
   Google Scholar
• BROGDEN, R. N., HL, R. C., SPEIGHT, T. M. and AVERY, G. S., 1979, Naproxden up to date: A review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs, 18, 241–277.
   PubMed Web of Science ®Google Scholar
• BROSEN, K., ZEUGIN, T. and MEYER, U. A., 1992, Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical Pharmacology and Therapeutics, 49, 609–617.
   Web of Science ®Google Scholar
• BUTLER, M. A., IWASAKI, M., GUENGERICH, F. P. and KADLUBAR, F. F., 1989, Human cytochrome P450PA (P450IA2), the phenacetin 0-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy of Sciences, USA, 86, 7696–7700.
   PubMed Web of Science ®Google Scholar
• CAMPBELL, M. E., SPEILBERG, S. P. and KALO W., 1987, A urinary metabolite ratio that reflects systemic caffeine clearance. Clinical Pharmacology and Therapeutics, 42, 157–165.
   PubMed Web of Science ®Google Scholar
• CARRIERE, V., GOASDUFF, T., RATANASAVANH, D., MOREL, F., GAUTIER, J.-C., GUILLOUZO, A., BEAUNE, P. and BERTHOU, F., 1993, Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chemical Research and Toxicology, 6, 852–857.
   Google Scholar
• CATTEAU, A., BECHET, Y. C., POISSON, N., BETCHEL, P. R. and BONAITI -PELLIE, C., 1995, A population and family study of CYP1A2 using caffeine urinary metabolites. European Journal of Clinical Pharmacology, 47, 423–430.
   Google Scholar
• CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMATAKI, T. and ISHIZAKI, T., 1993, Oxidative metabolism of omeprazole in human liver microsomes : cosegregation with (S)-mephenytoin 4"-hydroxylation. Journal of Pharmacology and Experimental Therapeutics, 266, 5323–59.
   Web of Science ®Google Scholar
• CHIBA, K., SAITOH, A., KOYAMA, E., TAM, M., HAYASHI, M. and ISHIZAKI, T., 1994, The role of (S)-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes : a two-enzyme analysis of N-demethylation and 2-hydroxylation. British Journal of Clinical Phar-macology, 37, 237–242.
   PubMed Web of Science ®Google Scholar
• CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterisation of the inhibition of 1A2 by furafylline. Xenobiotica, 24, 517–526.
   PubMed Web of Science ®Google Scholar
• CUPPY -VICKERY, J. R. and PouLos, T. L., 1995, Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Structural Biology, 2, 144–152.
   Google Scholar
• CURI-PEDROSA, R., DAUJAT, M., PICHARD, L., OURLIN, J. C., CLAIR, P., GERVOT, L., LESCA, P., DOIVIERGUE, J., JoYEux, H., FOURTAN1ER, G. and MAUREL, P., 1994, Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. Journal of Pharmacology and Experimental Therapeutics, 269, 384–392.
   Google Scholar
• DAHL, M.-L., TYBRING, G., ELWIN, C.-E., ALM, C., ANDREASSON, K., GYLLENPALM, M. and BERTILSSON, L., 1994, Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clinical Pharmacology and Therapeutics, 56, 176–183.
   PubMed Web of Science ®Google Scholar
• DALY, A. K., CHOLERTON, S., GREGORY, W. and IDLE, J. R., 1993, Metabolic polymorphisms. Pharmacology and Therapeutics, 57, 129–160.
   PubMed Web of Science ®Google Scholar
• DANESHIVIEND, T. K. and WARNOCK, D. W., 1988, Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics, 14, 13–34.
   PubMed Web of Science ®Google Scholar
• DE LA FORGE, M., JAQUEN, M. and MANSUY, D., 1983, Dual effects of macrolide antibiotics On rat liver cytochrome P450. Induction and formation of metabolite complexes: a structure-activity relationship. Biochemical Pharmacology, 32, 2309–2318.
   PubMed Web of Science ®Google Scholar
• DE WAZ1ERS, I., CUGNENC, P. H., YANG, C. S., LEROUX J.-P. and BEAUNE, P. H., 1990, Cytochrome P450 Isoenzymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues. Journal of Pharmacology and Experimental Therapeutics, 253, 387–394. DICKERSON, R. G., HOOPER, W. D., PATTERSON, M., EAD1E, M. J. and MAGUIRE, B., 1985, Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Therapeutic Drug Monitering, 7, 283–289.
   Google Scholar
• DOECKE, C. J., VERONESE, M. E., POND, S. M., MINERS, J. 0., BIRKETT, D. J., SANSOM, L. N. and McMANus, M. E., 1991, Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. British Journal of Clinical Pharmacology, 31, 124–130.
   Google Scholar
• EADE, 0. E., MADDISON, A., LEONARD, P. J. and WRIGHT, R., 1977, Ratio of urinary 6fl-hydroxy-corticosteroids in patients with liver disease. Digestion, 16, 169–174.
   Google Scholar
• EICHELBAUM, M., BERTILSSON, L., SAWE, J. and ZEKORN, C., 1982, Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clinical Pharmacology and Therapeutics, 31, 184–186.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM, M. and GROSS, A. S., 1990, The genetic polymorphisms of debrisoquine/sparteine metabolism-clinical aspects. Pharmacology and Therapeutics, 46, 377–394.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM, M., SPANNBRUCKER, N. and DENGLER, H. J., 1979b, Influence of the defective metabolism of sparteine on its pharmacokinetics. European Journal of Clinical Pharmacology, 16, 189–194.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM, M., SPANNBRUCKER, N., STEINCKE, B. and DENGLER, H. J., 1979a, Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16, 183–187.
   PubMed Web of Science ®Google Scholar
• ELLIS, S. W., HAYHURST, G. P., SMITH, G., LIGHTFOOT, T., WONG, M. M. S., SIMULA, A. P., ACKLAND M. J., S TERNBERG, M. J. E., LENNARD M. S., TUCKER, G. T. and WOLF, C. F., 1995, Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. Journal of Biological Chemistry, 270, 29055–29058.
   Google Scholar
• EVANS, D. A. P., MAHGOUB, A., SLOAN, T. P., IDLE, J. R. and SMITH, R. L., 1980, A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics, 17, 102–105.
   Google Scholar
• EVANS, W. E. and RELLING, M. V., 1991, Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Phamacogenetics, 1, 143–148.
   PubMedGoogle Scholar
• FRANTZ, A. G., KATZ, F. H. and JAILER, J. W., 1960,6/3-hydroxycortisol: High levels in human urine in pregnancy and toxemia. Proceedings of the Society for Experimental Biology and Medicine, 105, 41–43.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN, H., GREENBLATT, D. J. and BURSTEIN, E. S., 1986, Population study of triazolam pharmacokinetics. British Journal of Clinical Pharmacology, 22, 639–642.
   PubMed Web of Science ®Google Scholar
• GED, C., ROUILLON, M., PICHARD, L., COMBALBERT, J., BRESSOT, N., BORIES, P., MICHEL, H., BEAUNE, P. and MAUREL, P., 1989, The increase in urinary excretion of 6/3-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. British Journal of Clinical Pharmacology, 28, 373–387.
   PubMed Web of Science ®Google Scholar
• GERBER -TARAS, E., PARK, B. K. and OHNHAUS, E. E., 1981, The estimation of 6/3-hydroxycortisol in urine—a comparison of two methods: High performance liquid chromatography and radio-immunoassay. Journal of Clinical Chemistry and Clinical Biochemistry, 19, 525–527.
   Google Scholar
• GIBSON, G. G. and TAMBURINI, P. P., 1984, Cytochrome P-450 spin state: inorganic biochemistry of haem iron ligation and functional significance. Xenobiotica, 14, 27–47.
   PubMed Web of Science ®Google Scholar
• GIRRE, C., LUCAS, D., HISPARD, E., MENEZ, C., DALLY, S. and MENEZ, J. F., 1994, Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochemical Pharmacology, 47, 1503–1508.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN, J. A., FALETTO, M. B., ROMKES -SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry, 33, 1743–1752.
   Google Scholar
• GONZALEZ, F. J., 1992, Human cytochromes P450: problems and prospects. Trends in Pharmacological Sciences, 13, 346–352.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J., SKODA, R. C., KIMURA, S., UMENO, M., ZANGER, U. M., NEBERT, D. W., GELBOIN H. V., HARDWICK, J. P. and MEYER, U. A., 1988, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442–446.
   Google Scholar
• GOLDSTEIN, J. A. and DE MORMS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285–299.
   PubMedGoogle Scholar
• GUENGERICH, F. P. and MACDONALD, T. L., 1990, Mechanisms of cytochrome P450 catalysis. FASEB Journal, 4, 2453–2459.
   PubMed Web of Science ®Google Scholar
• GUT, J., CATIN, T., DAYER, P., KRONBACH, T., ZANGER, U. and MEYER, U. A., 1986, Debrisoquine/sparteine type polymorphism of drug oxidation. Journal of Biological Chemistry, 261, 11734–11743.
   Google Scholar
• HARGREAVES, M. B., Jos, B. C., SMITH, D. A. and GESCHER, A., 1994, Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules. Drug Metabolism and Disposition, 22, 806–810.
   PubMed Web of Science ®Google Scholar
• HASEGAWA, T., HARA, K., KENMOCHI, T. and HATA, S., 1994, In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metabolism and Disposition, 22, 916–921.
   PubMed Web of Science ®Google Scholar
• HORSMAN, Y., DESAGER, J. P. and HARVENGT, C., 1992, Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6/3-cortisol in 102 healthy subjects on rifampicin. Pharmacological Toxicology, 7, 258–261.
   Google Scholar
• HOSODA, H., SAKAI, Y. and NAMBARA, T., 1981, A direct enzyme immunoassay of 6/3-hydroxycortisol in human urine. Chemistry and Pharmacology Bulletin (Tokyo), 29, 170–175.
   PubMed Web of Science ®Google Scholar
• HUNT, C. M., WATKINS, P. B., SAENGER ., P., STAVE, G. M., BARLASCINI, N., WATLINGTON, C. 0., WRIGHT, J. T. and GUZELIAN, P. S., 1992, Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18–23.
   Google Scholar
• INABA, T., JURIMA, M., MAHON, W. A. and KALO W., 1985, In vitro inhibition studies of two isozymes of human liver cytochrome P450, mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metabolism and Disposition, 13, 443–448.
   PubMed Web of Science ®Google Scholar
• INouE, S., INOKUMA, M., HARADA, T., SHIBUTANI, Y., YOSHITAKE, T., CHARLES, B., ISHIDA, J. and YAMAGUCHI, M., 1994, Simultaneous high performance liquid chromatographic determination of 6/3-hydroxycortisol and cortisol in urine with fluorescence detection and its application for estimating hepatic drug-metabolizing enzyme induction. Journal of Chromatography, 661,15–23.
   Web of Science ®Google Scholar
• IYUN, A. 0., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1986, Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clinical Pharmacology and Therapeutics, 40, 387–394.
   Google Scholar
• JACKSON, P. R., TUCKER, G. T., LENNARD, M. S. and WOODS, H. F., 1986, Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. British Journal of Clinical Pharmacology, 22, 541–550.
   PubMed Web of Science ®Google Scholar
• JONES, B. C., HAWKSWORTH, G., HORNE, V. A., NEWLANDS, A., MORSMAN, J., TUTE, M. S. and SMITH, D. A., 1996, Putative active site model for CYP2C9 (tolbutamide hydroxylase). Drug Metabolism and Disposition, 24, 1–7.
   PubMed Web of Science ®Google Scholar
• KALO W. and TANG, B.-K., 1993, The use of caffeine for enzyme assays: a critical appraisal. Clinical Pharmacology and Therapeutics, 53, 503–514.
   Google Scholar
• KATZ, F. H., LIPMAN, M. M., FRANrz, A. G. and JAILOR, J. W., 1962, The physiologic significance of 6)3-hydroxycortisol in human cortisol metabolism. Journal of Clinical Endocrinology and Metabolism, 22, 71–77.
   PubMed Web of Science ®Google Scholar
• KHARASCH, E. D., THUMMEL, K. E., MAUTZ, D. and BOSSE, S., 1994, Clinical enflurane metabolism by cytochrome P4502E1. Clinical Pharmacology and Therapeutics, 55, 434–40.
   PubMed Web of Science ®Google Scholar
• KHARASCH, E. D., THUMMEL, K. E., MHYRE, J. and LILLIBRIDGE, J. H., 1993, Single dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clinical Pharmacology and Therapeutics, 53, 643–650.
   PubMed Web of Science ®Google Scholar
• KIMURA, S., UMENO, M., SKODA, R. C., MEYER, U. A. and GONZALEZ, F. J., 1989, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and pseudogene. American Journal of Human Genetics, 45, 889–904.
   PubMed Web of Science ®Google Scholar
• KINIRONS, M. T., O'SHEA, D., DOWNING, T. E., FITZWILLIAM, A. T., JOELLENBECK, L., GROOPMAN J. D., WILKINSON, G. R. and WOOD, A. J. J., 1993, Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621–629.
   Google Scholar
• KOLARS, J. C., SCHMIEDLIN -REN, P., SCHUETZ, J. D., FANG, C. and WATKINS, P. B., 1992, Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation, 90, 1871–1878.
   Google Scholar
• KOLEY, A. P., BUTTERS, J. T. M., ROBINSON, R. C., MARKOWITZ, A. and FRIEDMAN, F. K., 1995, CO Binding kinetics of human cytochrome P450 3A4. Journal of Biological Chemistry, 270, 5014–5018.
   Google Scholar
• KONTAKE, A. N., SCHOELLER, D. A., LAMBERT, G. H., BAKER, A. L., SCHAFFER, D. D. and JOSEPHS, H., 1992, The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and non-smokers. Clinical Pharmacology and Therapeutics, 32, 261–269.
   Web of Science ®Google Scholar
• KOOP, D. R., 1992, Oxidative and reductive metabolism by cytochrome P450 2E1. F ASEB Journal, 6, 724–730.
   PubMed Web of Science ®Google Scholar
• KORZEKWA, K. R. and JONES, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1–18.
   PubMedGoogle Scholar
• KOYAMA, E., SOHN, D.-R., SHIN, S.-G., CHIBA, K., SHIN, J.-G., KIM, Y.-H., ECHIZEN, H. and ISHIZAKI T., 1994, Metabolic disposition of imipramine in Oriental subjects: relation to metoprolol a-hydroxylation and S-mephenytoin C.-hydroxylation phenotypes. Journal of Pharmacology and Experimental Therapeutics, 271, 860–867.
   Google Scholar
• KRIVORUK, Y., KINIRONS, M. T., WOOD, A. J. J. and WOOD, M., 1994, Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clinical Pharmacology and Therapeutics, 56, 608–614.
   Google Scholar
• KUNZE, K. L. and TRAGER, W. F., 1993, Isoform selective mechanism based inhibition of human cytochrome P4501A2 by furafylline. Chemical Research in Toxicology, 6, 649–656.
   PubMed Web of Science ®Google Scholar
• KUPFER, A., SCHMID, B. and PFAFF, G., 1986, Pharmacogenetics of dextromethorphan 0-demethylation in man. Xenobiotica, 16, 421–433.
   PubMed Web of Science ®Google Scholar
• LEE, C., 1995, Urinary 6/3-hydroxycortisol in humans: analysis, biological variations, and reference ranges. Clinical Biochemistry, 28, 49–54.
   PubMed Web of Science ®Google Scholar
• LEEMAN, T. D., TRANSON, C., BONNABRY, P. and DAYER, P., 1993, A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steriodal anti-inflammatory drugs. Drugs in Experimental Clinical Research, 19, 189–195.
   PubMedGoogle Scholar
• LELO, A., MINERS, J. 0., ROBSON, R. A. and BIRKETT, D. J., 1986, Quantitative assessment of caffeine partial clearances in man. British Journal of Clinical Pharmacology, 22, 183–186.
   Google Scholar
• LIDE, D. R., 1990–91, Chemical Rubber Company Handbook of Chemistry and Physics (Boca Raton: CRC Press).
   Google Scholar
• LOWN, K., KOLARS, J., TURGEON, D. K., MERION, R., WRIGHTON, S. A. and WATKINS, P. B., 1992, The erythromycin breath test selectively measures P450 IIIA in patients with severe liver disease. Clinical Pharmacology and Therapeutics, 51, 229–238.
   PubMed Web of Science ®Google Scholar
• LOWN, K. S., KOLARS, J. C., THUMMEL, K. E., BARNETT, J. L., KUNZE, K. L., WRIGHTON, S. A. and WATKINS, P. B., 1992, Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowl. Drug Metabolism and Disposition, 22, 947–955.
   Web of Science ®Google Scholar
• LOWN, K. S., THUMMEL, K. E., BENEDICT, P. E., SHEN, D. D., TURGEON, D. K., BERENT, S. and WATKINS, P. B. 1995, The erythromycin breath test predicts the clearance of midazolam. Clinical Pharmacology and Therapeutics, 57, 16–24.
   PubMed Web of Science ®Google Scholar
• LUCAS, D., BERTHOU, F., DREANO, Y., LOZACH, P., VOLANT, A. and MENEZ, J. F., 1993, Comparison of levels of cytochromes P450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical liver samples. Alcohol in Clinical and Experimental Research, 17, 900–905.
   Google Scholar
• MACKMAN, R., Guo, Z., GUENGERICH, F. P., ORTIZ DE MONTELLANO, P. R., 1996, Active site topology of human cytochrome P450 2E1. Chemical Research in Toxicology, 9, 223–226.
   PubMed Web of Science ®Google Scholar
• MAHGOUB, A., IDLE, J. R., DRING, L. G., LANCASTER, R. and SMITH, R. L., 1977, Polymorphic hydroxylation of debrisoquine in man. Lancet, ii, 584–586.
   Google Scholar
• MANNERS, C. N., PAYLING, D. W. and SMITH, D. A., 1988, Distribution coefficient, a convenient term for the relation of predictable physico-chemical properties to metabolic processes. Xenobiotica, 18, 331–335.
   PubMed Web of Science ®Google Scholar
• MCGOURTY, J. C., SILAS, J. H., LENNARD, M. S., TUCKER, G. T. and WOODS, H. F., 1985, Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. British Journal of Clinical Pharmacology, 20, 555–566.
   PubMed Web of Science ®Google Scholar
• MuMANus, M. E., BURGESS, W. M., VERONESE, M. E., HUGGETT, A., QUATTROCHI, L. C. and TUKEY R. H., 1990, Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome P-450. Cancer Research, 50, 3367–3376.
   Google Scholar
• MURRAY, M., 1984, Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metabolism Reviews, 18, 55–81.
   Web of Science ®Google Scholar
• NAKAMURA, J. and YAKATA, M., 1989, Assessing adrenocortical activity by determining levels of urinary free cortisol and urinary 6/3-hydroxycortisol. Acta Endocrinology, 120, 277–83.
   PubMedGoogle Scholar
• NELSON E. and O'REILLY, I., 1961, Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide adminstration. Journal of Pharmacology and Experimental Therapeutics, 132, 103–109.
   PubMed Web of Science ®Google Scholar
• NOTARIANNI, L. J., OLIVER, S. E., DOBROCKY, P., BENNETT, B. N. and SILVERMAN, B. W., 1995, Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. British Journal of Clinical Pharmacology, 39, 65–69.
   PubMed Web of Science ®Google Scholar
• NSABIYUMVA, F., FURET, Y., AUTRER, E., JONVILLE, A. P. and BRETEAU, M., 1991, Oxidative polymorphism of detromethorphan in a Burundi population. European Journal of Clinical Pharmacology, 41, 75–77.
   PubMed Web of Science ®Google Scholar
• OLKKOLA, K. T., ARANKO, K., LUURILA, H., HILLER, A., SAARNIVAARA, L., HIMBERG, J. J. and NEUVONEN, P. J., 1993, A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics, 53, 298–305.
   PubMed Web of Science ®Google Scholar
• O'SHEA, D., DAVIS, S. N., KIM, R. B. and WILKINSON, G. R., 1994, Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe for CYP2E1 activity. Clinical Pharmacology and Therapeutics, 56, 359–367.
   Google Scholar
• PARK, B. K., 1982, Assessment of urinary 6/3-hydroxycortisol as an in vivo index of mixed function oxidase activity. British Journal of Clinical Pharmacology, 12, 97–102.
   Web of Science ®Google Scholar
• PARK, B. K. and KITTERINGHAM, N. R., 1989, Relevance and means of assessing induction and inhibition of drug metabolism in man. In G. G. Gibson (ed.), Progress in Drug Metabolism 11 (London: Taylor and Francis), pp. 1–59.
   Google Scholar
• PARK, B. K. and KITTERINGHAM, N. R., 1990, Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. Xenobiotica, 20, 1171–1185.
   PubMed Web of Science ®Google Scholar
• PETER, R., BOCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450I1E1. Chemical Research and Toxicology, 3, 566–573.
   PubMed Web of Science ®Google Scholar
• PFANDL, B., MORIKE, K., WI, D., SCHARECK, W. and BREYER -PFAFF, U., 1992, Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotka, 22, 721–730.
   Google Scholar
• PIRMOHAMED, M., WILLIAMS, D., MADDEN, S., TEMPLETON, E. and PARK, B. K., 1995, Metabolism and bioactivation of clozapine by human liver in vitro. Journal of Pharmacology and Experimental Therapeutics, 272, 984–990.
   PubMed Web of Science ®Google Scholar
• RENNER, E., WIETHOLTZ, H., HUGUENIN, P., ARNAUD, M. J. and PREISIG, R., 1984, Caffeine: a model compound for measuring liver function. Hepatology, 4, 38–46.
   PubMed Web of Science ®Google Scholar
• ROST, K. L. and ROOTS, I., 1994, Accelerated caffeine metabolism after omeprazole treatment as indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clinical Pharmacology and Therapeutics, 55, 402–411.
   PubMed Web of Science ®Google Scholar
• SARKAR, M. A. and JACKSON, B. J., 1994, Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metabolism and Disposition, 22, 827–833.
   PubMed Web of Science ®Google Scholar
• SAENGER, P., FORESTER, E. and KREAM, J., 1981,6fl-hydroxycortisol: a non-invasive indicator of enzyme induction. Journal of Clinical Endocrinology and Metabolism, 52, 381–384.
   PubMed Web of Science ®Google Scholar
• SCHMID, B., BIRCHER, J., PREISIG, R. and KUPFER, A., 1985, Polymorphic dextromethorphan metabolism: co-segregation of oxidative 0-demethylation with debrisoquin hydroxylation. Clinical Phar-macology and Therapeutics, 38, 618–624.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES,
   Google Scholar
• D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human cytochrome P-450 enzymes involved in the oxidations of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• SHOU, M., GROGAN, J. A., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33, 6450–6455.
   PubMed Web of Science ®Google Scholar
• SIMOOYA O. O., NJUNN, E., HODJEGAN, A. R., LENNARD, M. S. and TUCKER, G. T., 1993, Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics, 3, 205–208.
   PubMedGoogle Scholar
• SINDRUP, S. H., BROSEN, K. and GRAM, L. F., 1992, Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics, 51, 288–295.
   PubMed Web of Science ®Google Scholar
• SINDRUP, S. H., BROSEN, K., GRAM, L. F., HALLAS, J., SKJELBO, E., ALLEN, A., ALLEN, G. D., COOPER, S. M., MELLOWS, G., TASKER, C. G. and ZUSSMAN, B. D., 1992, The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics, 51, 278–287.
   PubMed Web of Science ®Google Scholar
• SKJELBO, E., BROSEN, K., HALLAS, J. and GRAM, L. F., 1991, The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clinical Pharmacology and Therapeutics, 49, 18–23.
   PubMed Web of Science ®Google Scholar
• SKJELBO, E., GRAM, L. F. and BROSEN, K., 1993, The N-demethylation of imipramine correlates with the oxidation of (S)-mephenytoin (S1/2 ratio). A population study. British Journal of Clinical Pharmacology, 35, 331–334.
   PubMed Web of Science ®Google Scholar
• SLOAN, T. P., LANCASTER, R., SHAH, R. R., IDLE, J. R. and SMITH, R. L., 1983, Genetically determined oxidation capacity and the disposition of debrisoquine. British Journal of Clinical Pharmacology, 15, 443–450.
   PubMed Web of Science ®Google Scholar
• SMITH, D. A. and JONES, B. C., 1992, Speculations on the substrate structure-activity relationship (SSAR) of Cytochrome P450 enzymes. Biochemical Pharmacology, 44, 2089–2098.
   PubMed Web of Science ®Google Scholar
• SMITH, R. L., 1986, Introduction. Xenobiotica, 16, 361–365.
   Web of Science ®Google Scholar
• SOHN, D.-R., SHIN, S.-G., PARK, C.-W., KUSAKA, M., CHIBA, K. and ISHIZAKI, T., 1991, Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. British Journal of Clinical Pharmacology, 32, 504–507.
   PubMed Web of Science ®Google Scholar
• STROBL, G. R., VON KRUEDENER, S., SToCKIGT, J., GUENGERICH, F. P. and WOLFF, T., 1993, Development of a pharmacophore for inhibition of human liver cytochrome P450 2D6: molecular modelling and inhibition studies. Journal of Medicinal Chemistry, 36, 1136–1145.
   PubMed Web of Science ®Google Scholar
• SWINNEY, D. C., So, 0.-Y., WATSON, D. M., BERRY, P. W., WEBB, A. S., KERTESZ, D. J., SHELTON,
   Google Scholar
• E. J., BURTON, P. M. and WALKER, K. A. M., 1994, Selective inhibition of mammalian lanosterol 14 a-demethylase by RS-21607 in vitro and in vivo. Biochemistry, 33, 4702–4713.
   Google Scholar
• TASSANEEYAKUL W., BIRKETT, D. J., MEMANus, M. E., TASSANEEYAKUL W., VERONESE, M. E., ANDERSSON, T., TUKEY, R. H. and MINERS, J. 0., 1994, Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochemical Pharmacology, 47, 1767–1776.
   Google Scholar
• TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., DOECKE, C. J., MCMANUS, M. E., SANSOM, L. N. and MINERS, J. 0., 1992, Co-regulation of phenytoin and tolbutamide metabolism in humans. British Journal of Clinical Pharmacology, 34, 494–498.
   Google Scholar
• THOMAS, R. C. and 'REDA, G. J., 1966, The metabolic fate of tolbutamide in man and rat. Journal of Medicinal Chemistry, 9, 507–510.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. D., KUNZE, K. L., TRAGER, W. F., HARTWELL, P. S., RAISYS V. A., MARSH, C. L., McVicAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS Jr., R. L., 1994, Use of midazolam as a human cytochrome P450 3A probe: 1. In vitro—in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549–556.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., PODOLL, T. MD., KUNZE, K. L., TRAGER, W. F., BACCHI, C. E., MARSH, C. L., McVicAR, J. P., BARR, D. M., PERKINS, J. D. and CARITHERS Jr., R. L., 1994, Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. journal of Pharmacology and Experimental Therapeutics, 271, 557–566.
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., BACCHI, C. E., McVicAR, J. P., MARSH, C. L., PERKINS, J. D. and CARITHERS, R. L., 1992, Induction of human hepatic P4503A3/4 by phenytoin. Hepatology, 16, 160A (abstract).
   Google Scholar
• THUMMEL, K. E., SHEN, D. D., CARITHERS, R. L., HARTWELL, P., PODOLL, T. D., TRAGER, W. F. and KUNZE, K. L., 1993, Prediction of in vivo midazolam clearance from hepatic CYP3A content and midazolam 1-hydroxylation activity in liver transplant patients. IS SX Proceedings, 4, 235–230.
   Google Scholar
• TJIA, J. F., WEBBER, I. R. and BACK, D. J., 1991, Cyclosporin metabolism by the gastrointestinal mucosa. British Journal of Clinical Pharmacology, 31, 344–346.
   PubMed Web of Science ®Google Scholar
• TOUCHSTONE, J. L. and BLAKEMORE, W. S., 1961, Urinary 6/3-hydroxycortisol in adrenocortical hyperfunction. Journal of Clinical Endocrinology and Metabolism, 21, 263–270.
   PubMed Web of Science ®Google Scholar
• TURGEON, J., FISET, C., GIGUERE, R., GILBERT, M., MOERIKE, K., ROULEAU, J. R., KROEMER, H. K., EICHELBAU M., GRECH -BELANGER, 0. and BELANGER, P. M., 1991, Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. Journal of Pharmacology and Experimental and Therapeutics, 259, 789–798.
   Google Scholar
• TURGEON, D. K., LEICHTMAN, A. B. and BLAKE, D. S., 1994, Prediction of interpatient and intrapatient variation in OG 37325 dosing requirements by the erthromycin breath test. Transplantation, 57, 1736–1741.
   PubMed Web of Science ®Google Scholar
• TYBRING, G. and BERTILSSON, L., 1992, A methodological investigation on the estimation of the (S)-mephenytoin hydroxylation phenotype using the urinary SM ratio. Pharmacogenetks, 2, 241–243.
   PubMedGoogle Scholar
• TYNDALE, R. F., SUNAHARA, R., INABA, T., KALOW, W., GONZALEZ, F. J. and NIZNIK, H. B., 1991, Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by ( —)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Molecular Pharmacology, 40, 63–68.
   PubMed Web of Science ®Google Scholar
• VERONESE, M. E., MINERS, J. 0., RANDLES, D., GREGOV, D. and BIRKETT, D. J., 1990, Validation of the tolbutamide metabolic ratio for population screening with the use of sulfaphenazole to produce model phenotypic poor metabolizers. Clinical Pharmacology and Therapeutics, 47, 403–411.
   Google Scholar
• VON -M OLTKE, L. L., GREENBLATT, D. J., DUAN, S. X., HARMATZ, J. S. and S HADER, R. I., 1994, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. Journal of Clinical Pharmacology, 34, 1222–1227.
   Google Scholar
• DE VRIES, J. D., SALPHATI, L., HORIE, S., BECKER, C. E. and HOENER, B.-A., 1994, Variability in the disposition of chlorzoxazone. Biopharmaceutics and Drug Disposition, 15, 587–597.
   Google Scholar
• WADE, R. C., 1990, Solvation of the active site of cytochrome P450-cam. Journal of Computer-Aided Molecular, 4, 199–204.
   PubMed Web of Science ®Google Scholar
• WALKER, D. K., JONES, B. C. and SMITH, D. A., 1995, Differentiation of compounds which bind to P450 isozymes CYP2C9 and CYP3A4 by physicochemical properties. British Journal of Clinical Pharmacology, 40, 178P.
   Google Scholar
• WANG, M.-H., WADE, D., CHEN, L., WHITE, S. and YANG, C. S. M., 1996, Probing the active site of rate and human cytochrome P450 2E1 with alcohols and carboxylic acids. Archives of Biochemistry and Biophysics, 317, 299–304.
   Web of Science ®Google Scholar
• WATKINS, P., 1994, Noninvasive tests of CYP3A enzymes. Pharmacogenetks, 4, 171–184.
   PubMedGoogle Scholar
• WATKINS P. B., HAMILTON, T. A., ANNESLEY, T. M., ELLIS, C. N., KOLARS, J. C. and VORRHEES, J. J., 1990, The erythromycin breath test as a predictor of cyclosporin A blood levels. Clinical Pharmacology and Therapeutics, 48, 120–129.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., MURRAY, S. A., WINKELMAN, L. G., HEUMAN, D. M., WRIGHTON, S. A. and GUZELIAN P. S., 1989, Erythromycin breath test as an assay of glucurocorticoid-inducible liver cytochromes P450. Journal of Clinical Investigation, 83, 688–697.
   Google Scholar
• WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1993, Cytochrome P450 2C9 is responsible for the hydroxylation of the naphthoquinone antimalarial 58C80 in human liver. Biochemical Phar-macology, 46, 1183–1197.
   PubMed Web of Science ®Google Scholar
• WEBER, I. R., PETERS, W. H. M. and BACK, D. J., 1992, Cyclosporin metabolism by human gas-trointestinal mucosal microsomes. British Journal of Clinical Pharmacology, 33, 661–664.
   Google Scholar
• XIAODONG, S., GATTI, G., BARTOLI, A., CIPOLLA, G., CREMA, G. and PERUCCA, E., 1994, Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Therapeutic Drug Monitoring, 16, 248–250.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., Guo, Z. and GUENGERICH, F. P., 1995, Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metabolism and Disposition, 23, 438–440.
   PubMed Web of Science ®Google Scholar
• YUN, CH., OKERHOLM, R. A. and GUENGERICH, F. P., 1993, Oxidation of the antihistiminic drug terfenadine in human liver microsomes: role of cytochrome P450 3A(4) in the N-dealkylation and C-hydroxylation. Drug Metabolism and Disposition, 21, 403–409.
   PubMed Web of Science ®Google Scholar
• YUN, CH., WOOD, M., WOOD, A. J. J. and GUENGERICH, F. P., 1992, Identification of the pharmaco-genetic determinants of alfentanil metabolism: cytochrome P-4503A4. An explanation of the variable elimination clearance. Anaesthesiology, 77, 467–474.
   Google Scholar
• ZUMOFF, B., BRADLOW, L., GALLAGHER, T. F. and HELLMAN, L., 1967, Cortisol metabolism in cirrhosis. Journal of Clinical Investigation, 46, 1735–1743.
   PubMed Web of Science ®Google Scholar